Lee Tae Seung, Kim Jun Yeol, Lee Myeong Hwan, Cho In Rae, Paik Woo Hyun, Ryu Ji Kon, Kim Yong-Tae, Lee Sang Hyub
Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Cancers (Basel). 2023 Sep 25;15(19):4708. doi: 10.3390/cancers15194708.
Savolitinib is a highly selective small molecule inhibitor of the mesenchymal epithelial transition factor (MET) tyrosine kinase, primarily developed for the treatment of non-small cell lung cancer (NSCLC) with mutations. It is also being investigated as a treatment for breast, head and neck, colorectal, gastric, pancreatic, and other gastrointestinal cancers. In both preclinical and clinical studies, it has demonstrated efficacy in lung, kidney, and stomach cancers. Savolitinib is an oral anti-cancer medication taken as a 600 mg dose once daily. It can be used as a monotherapy in patients with non-small cell lung cancer with mutations and in combination with epidermal growth factor receptor (EGFR) inhibitors for patients who have developed resistance to them. Furthermore, savolitinib has shown positive results in gastric cancer treatment, particularly in combination with docetaxel. As a result, this review aims to validate its efficacy in NSCLC and suggests its potential application in other gastrointestinal cancers, such as pancreatic cancer, based on related research in gastric and renal cancer.
赛沃替尼是一种对间充质上皮转化因子（MET）酪氨酸激酶具有高度选择性的小分子抑制剂，主要用于治疗具有特定突变的非小细胞肺癌（NSCLC）。它也正在被研究用于治疗乳腺癌、头颈癌、结直肠癌、胃癌、胰腺癌和其他胃肠道癌症。在临床前和临床研究中，它已在肺癌、肾癌和胃癌中显示出疗效。赛沃替尼是一种口服抗癌药物，每日服用一次，剂量为600毫克。它可用于治疗具有特定突变的非小细胞肺癌患者的单药治疗，也可与表皮生长因子受体（EGFR）抑制剂联合用于对其产生耐药性的患者。此外，赛沃替尼在胃癌治疗中显示出积极结果，特别是与多西他赛联合使用时。因此，本综述旨在验证其在非小细胞肺癌中的疗效，并根据胃癌和肾癌的相关研究，提出其在其他胃肠道癌症（如胰腺癌）中的潜在应用。
